Kura Oncology price target raised to $40 from $37 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Kura Oncology (KURA) to $40 from $37 and keeps a Buy rating on the shares. The firm says the KOMET-001 “sneak peek points in the right direction.” The company announced positive topline results from the registration-enabling Phase 2 KOMET-001 clinical trial evaluating ziftomenib monotherapy in relapsed/refractory acute myeloid leukemia with a nucleophosmin 1 mutation patients, the analyst tells investors in a research note.